MSF among health groups appealing European Patent Office decision to uphold...
NEW YORK/PARIS, DECEMBER 5, 2018—Six organizations appealed today the European Patent Office’s September decision to uphold US pharmaceutical corporation Gilead Science’s patent on the key hepatitis C...
View ArticleJapans Ministry of Health, Labour and Welfare Approves Gileads Epclusa...
Until now, no treatment option has been available in Japan for the treatment of chronic HCV infection with decompensated cirrhosis, and there have been limited treatment options for patients with...
View ArticleCost-Effectiveness Opinions by French National Health Authority Improved...
Lessons from the Recent Uptake of Health Economic Evaluation of Innovative Drugs in the French Regulatory Framework.read more
View ArticleGilead's Asegua Therapeutics selected to partner with health department for...
The Louisiana Department of Health and Department of Corrections announced today their selection of Asegua Therapeutics LLC (a subsidiary of Gilead Sciences, Inc.) as their hepatitis C subscription...
View ArticleGilead to Present New Data From Multiple Liver Disease Research and...
More Than 35 Abstracts Across NASH, PSC and Viral Hepatitis Reflect Ongoing Commitment to Advancing Liver Disease Research and Patient Care --read more
View ArticleGilead Presents New Data on Viral Hepatitis at the International Liver...
These results, along with data from Gilead’s HBV cure research program, will be presented at The International Liver Congress™ (ILC) 2019 in Vienna, Austria.read more
View ArticleLouisiana Launches Hepatitis C Innovative Payment Model With Asegua...
Today, Governor John Bel Edwards joined Secretary Rebekah Gee of the Louisiana Department of Health, Secretary James LeBlanc of the Louisiana Department of Corrections, and Asegua Therapeutics LLC, a...
View ArticleLouisiana Departments of Health and Corrections seeking feedback on Louisiana...
The Louisiana Departments of Health and Corrections are welcoming public comment on the Louisiana Hepatitis C Elimination Plan, which was released today for review. This comprehensive, evidence-based...
View ArticleStates innovative payment agreement with Asegua Therapeutics for hepatitis C...
More Louisiana residents living with hepatitis C have been able to receive life-saving treatment because of Louisiana’s innovative payment model for the medications that cure this illness.read more
View ArticleChina National Medical Products Administration Approves Vosevi (Sofosbuvir,...
The approval of Vosevi in China is supported by two global Phase 3 studies, POLARIS-1 and POLARIS-4, which evaluated 12 weeks of treatment with Vosevi among adults with HCV genotype 1-6 with or without...
View ArticleU.S. Food And Drug Administration Approves Epclusa (Sofosbuvir/Velpatasvir)...
Pediatric approval of protease inhibitor-free, pan-genotypic, pan-fibrotic, once-daily regimen supports HCV elimination efforts by providing critical option for broad range of populations --read more
View ArticleFDA Approves New Treatment for Pediatric Patients with Any Strain of Hepatitis C
The U.S. Food and Drug Administration today approved a supplemental application for Epclusa (sofosbuvir and velpatasvir) to treat hepatitis C virus (HCV) in children ages 6 years and older or weighing...
View ArticleIncreasing access to hepatitis C treatment in Ukraine
MSF hepatitis C patient Ihor Skalko peers around the corner of his kitchen. Mykolaiv, Ukraine, July 2018. © Aleksandr Glyadyelov/MSFread more
View ArticleA Safe and Effective Cure for Hep-C During Pregnancy
PITTSBURGH – Critics of the new recommendation to screen all pregnant women for hepatitis C — a lifelong infection that attacks the liver — argue that it’s wasteful to test for a disease among a...
View ArticleGilead Implements Contract Pharmacy Integrity Initiative for Branded...
Gilead recognizes the important role of the 340B program in providing medicines for individuals with low incomes. The 340B program has grown rapidly in recent years, and a well-documented lack of...
View Article
More Pages to Explore .....